This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Clovis Oncology stock | $4.42

Own Clovis Oncology stock in just a few minutes.

Posted

Fact checked

Clovis Oncology, Inc is a biotechnology business based in the US. Clovis Oncology shares (CLVS) are listed on the NASDAQ and all prices are listed in US Dollars. Clovis Oncology employs 484 staff and has a trailing 12-month revenue of around USD$159.4 million.

How to buy shares in Clovis Oncology

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Clovis Oncology. Find the stock by name or ticker symbol: CLVS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Clovis Oncology reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$4.42, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Clovis Oncology, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Clovis Oncology. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Clovis Oncology share price

Use our graph to track the performance of CLVS stocks over time.

Clovis Oncology shares at a glance

Information last updated 2020-10-20.
Latest market close USD$4.42
52-week range USD$2.93 - USD$16.62
50-day moving average USD$6.0085
200-day moving average USD$6.7004
Wall St. target price USD$9
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-7.495

Buy Clovis Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Clovis Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Clovis Oncology price performance over time

Historical closes compared with the close of $4.42 from 2020-11-16

1 week (2020-11-25) -0.45%
1 month (2020-11-06) 3.76%
3 months (2020-09-04) -14.17%
6 months (2020-06-05) -33.83%
1 year (2019-12-05) -50.11%
2 years (2018-12-04) -77.89%
3 years (2017-12-05) -92.34%
5 years (2015-12-04) -86.98%

Is Clovis Oncology under- or over-valued?

Valuing Clovis Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clovis Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Clovis Oncology's PEG ratio

Clovis Oncology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.13. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Clovis Oncology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Clovis Oncology financials

Revenue TTM USD$159.4 million
Gross profit TTM USD$113.1 million
Return on assets TTM -33.61%
Return on equity TTM -547.55%
Profit margin -241.69%
Book value $-0.564
Market capitalisation USD$504.5 million

TTM: trailing 12 months

Shorting Clovis Oncology shares

There are currently 39.2 million Clovis Oncology shares held short by investors – that's known as Clovis Oncology's "short interest". This figure is 3.3% up from 37.9 million last month.

There are a few different ways that this level of interest in shorting Clovis Oncology shares can be evaluated.

Clovis Oncology's "short interest ratio" (SIR)

Clovis Oncology's "short interest ratio" (SIR) is the quantity of Clovis Oncology shares currently shorted divided by the average quantity of Clovis Oncology shares traded daily (recently around 5.3 million). Clovis Oncology's SIR currently stands at 7.35. In other words for every 100,000 Clovis Oncology shares traded daily on the market, roughly 7350 shares are currently held short.

However Clovis Oncology's short interest can also be evaluated against the total number of Clovis Oncology shares, or, against the total number of tradable Clovis Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Clovis Oncology's short interest could be expressed as 0.44% of the outstanding shares (for every 100,000 Clovis Oncology shares in existence, roughly 440 shares are currently held short) or 0.4571% of the tradable shares (for every 100,000 tradable Clovis Oncology shares, roughly 457 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Clovis Oncology.

Find out more about how you can short Clovis Oncology stock.

Clovis Oncology share dividends

We're not expecting Clovis Oncology to pay a dividend over the next 12 months.

Clovis Oncology share price volatility

Over the last 12 months, Clovis Oncology's shares have ranged in value from as little as $2.93 up to $16.62. A popular way to gauge a stock's volatility is its "beta".

CLVS.US volatility(beta: 2.23)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Clovis Oncology's is 2.2339. This would suggest that Clovis Oncology's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Clovis Oncology overview

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site